TSMHT
IBRX icon

Thurston Springer Miller Herd & Titak’s ImmunityBio IBRX Stock Holding History

Thurston Springer Miller Herd & Titak’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-100
Closed -$632 – 1553
2024
Q2 		$632 Buy
+100
New +$659 ﹤0.01% 1442

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Thurston Springer Miller Herd & Titak's IBRX Position: Q3 2024 in Review

Thurston Springer Miller Herd & Titak sold out of ImmunityBio (IBRX) in Q3 2024, closing a stake of 100 shares — an estimated $632 sold.

Thurston Springer Miller Herd & Titak first reported a position in IBRX in Q2 2024 and held it in 1 quarter. The position peaked at $632 in Q2 2024. 181 funds tracked by Wall St. Rank hold IBRX as of Q3 2024.

  • Thurston Springer Miller Herd & Titak reported no remaining ImmunityBio position as of Q3 2024 after selling out during the quarter.
  • Thurston Springer Miller Herd & Titak sold 100 ImmunityBio shares in Q3 2024, an estimated $632.
  • Thurston Springer Miller Herd & Titak first reported a position in ImmunityBio in Q2 2024 and held it in 1 quarter.
  • Thurston Springer Miller Herd & Titak's ImmunityBio position peaked at $632 in Q2 2024.
  • 181 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2024.

Based on Thurston Springer Miller Herd & Titak's 13F filing for Q3 2024, filed 11 Oct 2024.